Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity
- PMID: 2862891
- PMCID: PMC1463880
- DOI: 10.1111/j.1365-2125.1985.tb02713.x
Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity
Abstract
Bopindolol is a potent and specific beta-adrenoceptor antagonist with partial agonist activity. In animal experiments it blocks both beta 1- and beta 2-adrenoceptors and possesses a long duration of action. In the present study in healthy volunteers bopindolol was about ten times more potent than pindolol in reducing isoprenaline-induced and exercise-induced tachycardia. In experiments on exercise-induced tachycardia an oral dose of 2 mg produced a near maximum reduction of exercise heart rate, occurring within 2 to 3 h of administration. With higher doses (up to 12 mg) the maximum effect was reached earlier (between 1 and 2 h). The long duration of action of bopindolol observed in animal studies was confirmed in man. Twenty-four hours after 4 and 10 mg bopindolol more than 2/3 of the maximum effect was still present. After 48 h 38% of the maximum effect of 4 mg and 50% of that of 12 mg remained. Even at 72 and 96 h exercise-induced tachycardia was still significantly lowered after both doses of the drug. When bopindolol was administered once daily for 5 days there was a slight increase in the maximum reduction of exercise-induced tachycardia during treatment with 1 mg/day but not with 4 mg/day, which produced a near maximum effect.
Similar articles
-
Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.Drugs. 1991 Jan;41(1):130-49. doi: 10.2165/00003495-199141010-00010. Drugs. 1991. PMID: 1706984 Review.
-
Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.Br J Clin Pharmacol. 1986 Jan;21(1):45-51. doi: 10.1111/j.1365-2125.1986.tb02821.x. Br J Clin Pharmacol. 1986. PMID: 2868747 Free PMC article.
-
Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.Arzneimittelforschung. 1989 Apr;39(4):454-7. Arzneimittelforschung. 1989. PMID: 2568836
-
[Beta-blocking actions and the partial agonist activity of bopindolol, a new beta-adrenoceptor antagonist, and its two metabolites].Nihon Yakurigaku Zasshi. 1989 Jul;94(1):27-33. doi: 10.1254/fpj.94.27. Nihon Yakurigaku Zasshi. 1989. PMID: 2571551 Japanese.
-
[Pharmacological characteristics of the long-acting beta-blocker "bopindolol"].Nihon Yakurigaku Zasshi. 1997 Jan;109(1):1-12. doi: 10.1254/fpj.109.1. Nihon Yakurigaku Zasshi. 1997. PMID: 9067994 Review. Japanese.
Cited by
-
The effect of density on the gastric emptying of single- and multiple-unit dosage forms.Pharm Res. 1986 Aug;3(4):208-13. doi: 10.1023/A:1016334629169. Pharm Res. 1986. PMID: 24271583
-
The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.Br J Clin Pharmacol. 1991 Jun;31(6):697-700. doi: 10.1111/j.1365-2125.1991.tb05596.x. Br J Clin Pharmacol. 1991. PMID: 1678272 Free PMC article.
-
Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action.Br J Clin Pharmacol. 1991 Dec;32(6):755-7. Br J Clin Pharmacol. 1991. PMID: 1685090 Free PMC article. Clinical Trial.
-
Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis.Eur J Clin Pharmacol. 1990;39(6):569-72. doi: 10.1007/BF00316097. Eur J Clin Pharmacol. 1990. PMID: 1982762
-
Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.Drugs. 1991 Jan;41(1):130-49. doi: 10.2165/00003495-199141010-00010. Drugs. 1991. PMID: 1706984 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources